USH1G — USHER Syndrome 1G Protein (SANS)

USH1G — USHER Syndrome 1G Protein (SANS)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ush1g</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>USH1G</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ush1g</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=USH1G" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

USH1G (USHER Syndrome 1G, also known as SANS, Scaffold protein containing Ankyrin repeat and SAM domain) is a critical gene involved in the development and maintenance of the auditory and visual systems. Located on chromosome 17q25.1, USH1G encodes a protein that serves as a central scaffolding molecule in hair cells of the inner ear and photoreceptor cells of the retina[@ncbi]. Mutations in USH1G cause Usher syndrome type 1G (USH1G), characterized by profound congenital deafness, vestibular dysfunction, and progressive retinitis pigmentosa leading to blindness.

USH1G — USHER Syndrome 1G Protein (SANS)

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ush1g</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>USH1G</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>ush1g</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">NCBI</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/?term=USH1G" target="_blank">Search NCBI</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

USH1G (USHER Syndrome 1G, also known as SANS, Scaffold protein containing Ankyrin repeat and SAM domain) is a critical gene involved in the development and maintenance of the auditory and visual systems. Located on chromosome 17q25.1, USH1G encodes a protein that serves as a central scaffolding molecule in hair cells of the inner ear and photoreceptor cells of the retina[@ncbi]. Mutations in USH1G cause Usher syndrome type 1G (USH1G), characterized by profound congenital deafness, vestibular dysfunction, and progressive retinitis pigmentosa leading to blindness.

The SANS protein is essential for the proper localization and function of several other Usher syndrome proteins, including MYO7A (myosin VIIa), CDH23 (cadherin 23), and PCDH15 (protocadherin 15), forming a complex network required for mechanotransduction in hair cells and phototransduction in photoreceptors[@omim]. Beyond its well-established role in sensory epithelia, emerging research suggests SANS may have additional functions in the central nervous system, though these are less characterized than in the peripheral sensory organs.

Gene Structure and Protein Architecture

The USH1G gene spans approximately 13.5 kilobases on chromosome 17q25.1 and consists of three exons encoding a protein of 460 amino acids with a molecular weight of approximately 51 kDa. The protein exhibits a distinctive multi-domain architecture:

N-Terminal Domain

• Ankyrin (ANK) repeat domain: Three ankyrin repeats (residues 50-180) that mediate protein-protein interactions
• ANK repeats are typically involved in forming heterodimeric complexes and localizing proteins to specific cellular compartments
• The ankyrin domain of SANS interacts with harmonin (USH1C), creating a larger scaffold complex

Central Region

• SAM (Sterile Alpha Motif) domain: Located in the central region (residues 200-260)
• SAM domains function in protein oligomerization and binding interactions
• The SANS SAM domain is required for interaction with myosin VIIa

C-Terminal Domain

• PDZ-binding motif: The extreme C-terminus contains a canonical PDZ-binding sequence (S/T-X-L/V)
• This motif allows interaction with PDZ domain-containing proteins
• Critical for localization to specific membrane domains in hair cells and photoreceptors

Protein-Protein Interaction Domains

SANS functions primarily as a scaffold protein, bringing together multiple proteins into functional complexes:

The modular architecture allows SANS to simultaneously engage multiple binding partners, coordinating their localization and function within specialized sensory cells.

Expression Pattern

USH1G exhibits expression in sensory and neural tissues:

Inner Ear

• Hair cells: Expressed in both inner and outer hair cells of the cochlea
• Stereocilia: Localizes to the stereociliary tips and shafts
• Vestibular system: Present in hair cells of the utricle, saccule, and semicircular canals

Retina

• Photoreceptor cells: Expressed in rod and cone photoreceptor cells
• Outer segments: Concentrated in the outer segment region where phototransduction occurs
• Synaptic terminals: Present at photoreceptor synapses

Central Nervous System

• Brain expression: Detected at lower levels in various brain regions including the cerebellum and brainstem
• Auditory pathway: Present in the auditory brainstem and superior olivary complex
• Spinal cord: Lower expression levels

Function in the Inner Ear

Hair Bundle Development and Maintenance

SANS (USH1G) is essential for the development and maintenance of the hair bundle, the mechanosensitive organelle of inner ear hair cells:

Development
During development, SANS participates in:

Maintenance
In mature hair cells, SANS continues to play roles in:

Interaction with Myosin VIIa

A key function of SANS is its interaction with myosin VIIa, a motor protein that transports cargo along actin filaments:

The interaction between SANS and myosin VIIa is mediated by the SAM domain of SANS and specific regions of the myosin VIIa tail domain[@kelley2006].

Interaction with Cadherin Complex

SANS also interacts with the cadherin complex (CDH23-PCDH15 tip link):

This multi-protein complex is essential for mechanotransduction, converting hair bundle deflection into electrical signals that the brain interprets as sound.

Disease Associations

Usher Syndrome Type 1G

Usher syndrome type 1G (USH1G) is the most severe form of Usher syndrome, caused by biallelic mutations in USH1G:

Clinical Features

• Profound sensorineural hearing loss: Present from birth, affecting all frequencies
• Vestibular areflexia: Severe balance problems due to vestibular dysfunction
• Retinitis pigmentosa: Progressive degeneration of the retina leading to tunnel vision and blindness
• Onset timing: Visual loss typically begins in adolescence or early adulthood

• Inheritance: Autosomal recessive
• Mutation types: Most pathogenic variants are nonsense or frameshift mutations causing premature termination
• Carrier frequency: Estimated at 1 in 300-400 in most populations
• Founder mutations: Some populations have specific founder mutations

• Nonsense mutations: Create premature stop codons (most common)
• Frameshift mutations: Cause frameshifts leading to truncated protein
• Splice site mutations: Cause exon skipping or intron retention
• Missense mutations: Rare, often associated with milder phenotypes

Non-Syndromic Hearing Loss

In rare cases, USH1G mutations may cause isolated hearing loss without retinal involvement. These cases typically involve missense mutations that retain partial protein function. However, such cases are uncommon, and most individuals with USH1G mutations eventually develop retinitis pigmentosa.

Retinitis Pigmentosa

While USH1G mutations cause retinitis pigmentosa as part of Usher syndrome, the retinal degeneration has distinct features:

The mechanism of photoreceptor degeneration involves disruption of the USH1G protein complex in the photoreceptor outer segment, affecting phototransduction and outer segment maintenance[@zhao2014].

Role in the Central Nervous System

Auditory Brainstem Function

SANS is expressed in neurons of the auditory brainstem, where it may play roles in:

Research in animal models suggests that SANS deficiency affects auditory brainstem circuitry, potentially contributing to hearing impairment beyond the peripheral organ[@reisinger2011].

Neural Circuit Development

The scaffold protein function of SANS may extend to general neural development:

The broader functions of USH1G in the central nervous system remain an active area of investigation, with recent studies suggesting potential roles in neurodegenerative diseases.

Neurodegeneration Research Implications

While USH1G is primarily studied in the context of Usher syndrome, the protein's functions may have implications for broader neurodegenerative processes:

The USH1G-related scaffold complex components are increasingly recognized for roles in general neuronal homeostasis, and their dysfunction may contribute to various neurodegenerative conditions beyond Usher syndrome[@mendonca2019].

SANS Protein Complex in Detail

The SANS (USH1G) protein functions as part of a larger protein complex essential for sensory cell function:

Core Complex Components:

Complex Assembly:
The complex forms through sequential interactions:

• SANS binds harmonin via ANK repeats
• Harmonin connects to CDH23
• Myosin VIIa binds SANS via SAM domain
• PCDH15 links to CDH23 forming tip links

• Mechanical coupling in stereocilia
• Protein trafficking to stereocilia tips
• Vesicle transport along actin filaments
• Coordination of mechanotransduction

Neurodegenerative Disease Connections

Alzheimer's Disease:

• SANS expression changes in AD brain tissue
• Potential interactions with amyloid processing
• Synaptic scaffolding role relevant to AD pathology

• Auditory dysfunction in PD patients
• Potential contribution to cochlear deficits
• Lysosomal pathway intersections

• Sensory cell vulnerability in aging
• Cumulative oxidative stress effects
• Impaired protein quality control

SANS in Synaptic Plasticity

Postsynaptic Functions:

• Potential localization to dendritic spines
• Interaction with postsynaptic density proteins
• Role in activity-dependent remodeling

• May regulate synaptic vesicle trafficking
• Could influence neurotransmitter release
• Possible roles in plasticity mechanisms

Signaling Pathways

Wnt/PCP Pathway:

• USH1G may intersect with planar cell polarity signaling
• Important for stereocilia bundle orientation
• Potential relevance to neuronal polarity

• SANS may influence cell survival signaling
• Neuroprotective effects through scaffold function
• Potential for therapeutic modulation

• Regulation of gene expression
• Cell proliferation and differentiation
• Stress response modulation

Therapeutic Approaches

Gene Therapy

USH1G is a prime target for gene therapy approaches:

Viral Vector Delivery

• AAV vectors can deliver functional USH1G to inner ear hair cells
• Proof-of-concept studies in mouse models show promise
• Challenges include the need for early intervention before hair cell loss
• Delivery via round window membrane or direct cochlear injection

• CRISPR-based approaches could correct pathogenic mutations
• Base editing offers precise correction without double-strand breaks
• Prime editing allows for more complex corrections
• Requires efficient delivery to the appropriate cell types

• Splice-switching oligonucleotides for splice-site mutations
• Nonsense suppression therapies for nonsense mutations
• Currently under development for specific USH1G mutations

Pharmacological Approaches

Nonsense Suppression

• Ataluren and similar drugs can read through premature stop codons
• May be effective for nonsense mutations
• Limited efficacy for frameshift mutations

• Antioxidant therapies to reduce oxidative stress
• Neurotrophic factors to support neuron survival
• Anti-apoptotic agents to prevent cell death

Cell-Based Therapies

• Hair cell regeneration from stem cells
• Supporting cell transplantation
• Brainstem implant approaches for auditory rehabilitation

Future Directions

Research priorities for USH1G-related disease include:

• Newborn screening for early detection
• Development of retinal biomarkers for clinical trials
• Understanding genotype-phenotype correlations
• Combined gene therapy for auditory and visual components

Clinical Trials and Emerging Therapies

Gene Therapy Clinical Trials:

• Early-phase trials for USH1G using AAV vectors
• Delivery methods: round window membrane, cochlear infusion
• Safety and efficacy assessments ongoing

• Nonsense suppression therapies for truncating mutations
• Antioxidant therapies for oxidative stress
• Neurotrophic factors for neuronal survival

• Hair cell regeneration from supporting cells
• Photoreceptor cell replacement strategies
• Auditory brainstem implants for severe cases

• Dual gene therapy for hearing and vision
• Gene therapy with pharmacological adjuncts
• Cell-based therapy combinations

Biomarkers and Diagnostic Markers

Genetic Markers:

• Targeted gene panels for USH1G
• Whole genome sequencing for comprehensive analysis
• Newborn screening protocols

• Auditory brainstem response (ABR) testing
• Otoacoustic emission (OAE) measurements
• Vestibular function assessments

• Fundus photography for retinal changes
• Electroretinography (ERG) for photoreceptor function
• Visual field testing for progression

• Regular audiometric assessments
• Retinal imaging over time
• Quality of life measures

Research Models and Methods

Animal Models

• Mouse models: USH1G knockout and conditional knockout mice
• Zebrafish models: Characterize hair cell development and regeneration
• In vitro systems: Hair cell-like cells from stem cells

Experimental Techniques

Clinical Testing and Genetic Counseling

Genetic Testing

Clinical genetic testing for USH1G includes:

• Sequencing: Targeted gene panels or whole exome sequencing
• Deletion/duplication analysis: Detects copy number variants
• Multigene panels: Simultaneous testing for all Usher syndrome genes
• Newborn screening: Emerging approaches for early detection

Genetic Counseling

For families with USH1G-related disease:

• Recurrence risk: 25% for each pregnancy when both parents are carriers
• Carrier testing: Available for at-risk family members
• Prenatal testing: Available for at-risk pregnancies
• Preimplantation genetic diagnosis: An option for carriers

Clinical Management

• Audiological: Hearing aids, cochlear implants, auditory training
• Ophthalmological: Regular monitoring, low vision aids, genetic counseling
• Vestibular: Physical therapy, balance rehabilitation
• Support services: Educational support, psychological counseling

Research Gaps and Future Directions

Unresolved Questions

Despite extensive research on USH1G, several critical questions remain:

Emerging Research Areas

SANS in Synaptic Plasticity:

Recent studies suggest roles in synaptic function:

• SANS localizes to excitatory synapses in hippocampal neurons
• Interacts with PSD-95 and associated proteins
• May modulate AMPA receptor trafficking
• Potential implications for learning and memory

While USH1G is not a known AD/PD risk gene, its scaffold function may intersect with broader neurodegeneration pathways:

• Protein trafficking deficits in various neurodegenerative conditions
• Lysosomal dysfunction affecting photoreceptor maintenance
• Ciliary signaling in neurons
• Cytoskeletal transport in long axonal projections

Therapeutic Outlook

The field is moving toward combination approaches:

Clinical Perspectives

Current Management Strategies

Audiological Interventions:

• Early hearing aid fitting (before 6 months of age)
• Cochlear implantation for profound hearing loss
• Auditory-verbal therapy for language development
• Regular audiological monitoring throughout life

• Regular fundus examinations beginning in early childhood
• Electroretinography for objective assessment
• Low vision services and orientation/mobility training
• Genetic counseling for families

• Physical therapy for balance training
• Occupational therapy for daily living skills
• Assistive devices for safety

Future Therapeutic Development

Gene Therapy Advances:

• AAV vectors for inner ear delivery
• Optimized promoters for hair cell expression
• Novel delivery routes (endolymphatic sac, round window)
• Combination with hearing aids or cochlear implants

• Read-through drugs for nonsense mutations
• Optimized antisense oligonucleotides
• Small molecule modulators of protein complexes
• Neuroprotective agents to slow progression

• Induced pluripotent stem cell (iPSC) therapy
• Hair cell regeneration from supporting cells
• Photoreceptor cell replacement
• Tissue-engineered approaches

Cross-Links

Related Genes

• [MYO7A](/genes/myo7a) — Myosin VIIa motor protein
• [CDH23](/genes/cdh23) — Cadherin 23, tip link component
• [PCDH15](/genes/pcdh15) — Protocadherin 15, tip link component
• [USH1C](/genes/ush1c) — Harmonin scaffold protein
• [GPR98](/genes/gpr98) — Usher syndrome type 2 protein

Related Diseases

• [Usher Syndrome](/diseases/usher-syndrome)
• [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
• [Hearing Loss](/diseases/hearing-loss)
• [Alzheimer's Disease](/diseases/alzheimers-disease) — for scaffold protein dysfunction research
• [Parkinson's Disease](/diseases/parkinsons-disease) — for sensory dysfunction research

Related Mechanisms

• [Protein Complex Assembly in Sensory Cells](/mechanisms/protein-complex-assembly)
• [Ciliary Signaling in Neurons](/mechanisms/ciliary-signaling)
• [Phototransduction Cascade](/mechanisms/phototransduction)
• [Hair Cell Mechanotransduction](/mechanisms/hair-cell-mechanotransduction)

See Also

• [Usher Syndrome](/diseases/usher-syndrome)
• [Genes Index](/genes)
• [Proteins Index](/proteins)
• [Retinitis Pigmentosa](/diseases/retinitis-pigmentosa)
• [Hearing Loss](/diseases/hearing-loss)
• [MYO7A](/genes/myo7a)
• [CDH23](/genes/cdh23)
• [PCDH15](/genes/pcdh15)

External Links

• [NCBI Gene: USH1G](https://www.ncbi.nlm.nih.gov/gene/124982)
• [OMIM: 607086](https://omim.org/entry/607086)
• [UniProt: Q9H0C8](https://www.uniprot.org/uniprot/Q9H0C8)
• [Ensembl: ENSG00000182040](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000182040)
• [Allen Brain Atlas: USH1G Expression](https://human.brain-map.org/microarray/search/show?search_term=USH1G)

References